Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice

Masashi Nakatani, Yuka Takehara, Hiromu Sugino, Mitsuru Matsumoto, Osamu Hashimoto, Yoshihisa Hasegawa, Tatsuya Murakami, Akiyoshi Uezumi, Shin'ichi Takeda, Sumihare Noji, Yoshihide Sunada, Kunihiro Tsuchida

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Myostatin is a potent negative regulator of skeletal muscle growth. Therefore, myostatin inhibition offers a novel therapeutic strategy for muscular dystrophy by restoring skeletal muscle mass and suppressing the progression of muscle degeneration. The known myostatin inhibitors include myostatin propeptide, follistatin, follistatin-related proteins, and myostatin antibodies. Although follistatin shows potent myostatin-inhibiting activities, it also acts as an efficient inhibitor of activins. Because activins are involved in multiple functions in various organs, their blockade by follistatin would affect multiple tissues other than skeletal muscles. In the present study, we report the characterization of a myostatin inhibitor derived from follistatin, which does not affect activin signaling. The dissociation constants (Kd) of follistatin to activin and myostatin are 1.72 nM and 12.3 nM, respectively. By contrast, the dissociation constants (Kd) of a follistatin-derived myostatin inhibitor, designated FS I-I, to activin and myostatin are 64.3 μM and 46.8 nM, respectively. Transgenic mice expressing FS I-I, under the control of a skeletal muscle-specific promoter showed increased skeletal muscle mass and strength. Hyperplasia and hypertrophy were both observed. We crossed FS I-I transgenic mice with mdx mice, a model for Duchenne muscular dystrophy. Notably, the skeletal muscles in the mdx/FS I-I mice showed enlargement and reduced cell infiltration. Muscle strength is also recovered in the mdx/FS I-I mice. These results indicate that myostatin blockade by FS I-I has a therapeutic potential for muscular dystrophy.

Original languageEnglish
Pages (from-to)477-487
Number of pages11
JournalFASEB Journal
Volume22
Issue number2
DOIs
Publication statusPublished - 01-02-2008

Fingerprint

Myostatin
Follistatin
Inbred mdx Mouse
Pathology
Muscle
Skeletal Muscle
Activins
Muscular Dystrophies
Muscle Strength
Transgenic Mice
Follistatin-Related Proteins
Cell Enlargement
Duchenne Muscular Dystrophy
Infiltration
Hypertrophy
Hyperplasia

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Nakatani, Masashi ; Takehara, Yuka ; Sugino, Hiromu ; Matsumoto, Mitsuru ; Hashimoto, Osamu ; Hasegawa, Yoshihisa ; Murakami, Tatsuya ; Uezumi, Akiyoshi ; Takeda, Shin'ichi ; Noji, Sumihare ; Sunada, Yoshihide ; Tsuchida, Kunihiro. / Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. In: FASEB Journal. 2008 ; Vol. 22, No. 2. pp. 477-487.
@article{cf6f17cf44aa4786ae80455e5208831c,
title = "Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice",
abstract = "Myostatin is a potent negative regulator of skeletal muscle growth. Therefore, myostatin inhibition offers a novel therapeutic strategy for muscular dystrophy by restoring skeletal muscle mass and suppressing the progression of muscle degeneration. The known myostatin inhibitors include myostatin propeptide, follistatin, follistatin-related proteins, and myostatin antibodies. Although follistatin shows potent myostatin-inhibiting activities, it also acts as an efficient inhibitor of activins. Because activins are involved in multiple functions in various organs, their blockade by follistatin would affect multiple tissues other than skeletal muscles. In the present study, we report the characterization of a myostatin inhibitor derived from follistatin, which does not affect activin signaling. The dissociation constants (Kd) of follistatin to activin and myostatin are 1.72 nM and 12.3 nM, respectively. By contrast, the dissociation constants (Kd) of a follistatin-derived myostatin inhibitor, designated FS I-I, to activin and myostatin are 64.3 μM and 46.8 nM, respectively. Transgenic mice expressing FS I-I, under the control of a skeletal muscle-specific promoter showed increased skeletal muscle mass and strength. Hyperplasia and hypertrophy were both observed. We crossed FS I-I transgenic mice with mdx mice, a model for Duchenne muscular dystrophy. Notably, the skeletal muscles in the mdx/FS I-I mice showed enlargement and reduced cell infiltration. Muscle strength is also recovered in the mdx/FS I-I mice. These results indicate that myostatin blockade by FS I-I has a therapeutic potential for muscular dystrophy.",
author = "Masashi Nakatani and Yuka Takehara and Hiromu Sugino and Mitsuru Matsumoto and Osamu Hashimoto and Yoshihisa Hasegawa and Tatsuya Murakami and Akiyoshi Uezumi and Shin'ichi Takeda and Sumihare Noji and Yoshihide Sunada and Kunihiro Tsuchida",
year = "2008",
month = "2",
day = "1",
doi = "10.1096/fj.07-8673com",
language = "English",
volume = "22",
pages = "477--487",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "2",

}

Nakatani, M, Takehara, Y, Sugino, H, Matsumoto, M, Hashimoto, O, Hasegawa, Y, Murakami, T, Uezumi, A, Takeda, S, Noji, S, Sunada, Y & Tsuchida, K 2008, 'Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice', FASEB Journal, vol. 22, no. 2, pp. 477-487. https://doi.org/10.1096/fj.07-8673com

Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. / Nakatani, Masashi; Takehara, Yuka; Sugino, Hiromu; Matsumoto, Mitsuru; Hashimoto, Osamu; Hasegawa, Yoshihisa; Murakami, Tatsuya; Uezumi, Akiyoshi; Takeda, Shin'ichi; Noji, Sumihare; Sunada, Yoshihide; Tsuchida, Kunihiro.

In: FASEB Journal, Vol. 22, No. 2, 01.02.2008, p. 477-487.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice

AU - Nakatani, Masashi

AU - Takehara, Yuka

AU - Sugino, Hiromu

AU - Matsumoto, Mitsuru

AU - Hashimoto, Osamu

AU - Hasegawa, Yoshihisa

AU - Murakami, Tatsuya

AU - Uezumi, Akiyoshi

AU - Takeda, Shin'ichi

AU - Noji, Sumihare

AU - Sunada, Yoshihide

AU - Tsuchida, Kunihiro

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Myostatin is a potent negative regulator of skeletal muscle growth. Therefore, myostatin inhibition offers a novel therapeutic strategy for muscular dystrophy by restoring skeletal muscle mass and suppressing the progression of muscle degeneration. The known myostatin inhibitors include myostatin propeptide, follistatin, follistatin-related proteins, and myostatin antibodies. Although follistatin shows potent myostatin-inhibiting activities, it also acts as an efficient inhibitor of activins. Because activins are involved in multiple functions in various organs, their blockade by follistatin would affect multiple tissues other than skeletal muscles. In the present study, we report the characterization of a myostatin inhibitor derived from follistatin, which does not affect activin signaling. The dissociation constants (Kd) of follistatin to activin and myostatin are 1.72 nM and 12.3 nM, respectively. By contrast, the dissociation constants (Kd) of a follistatin-derived myostatin inhibitor, designated FS I-I, to activin and myostatin are 64.3 μM and 46.8 nM, respectively. Transgenic mice expressing FS I-I, under the control of a skeletal muscle-specific promoter showed increased skeletal muscle mass and strength. Hyperplasia and hypertrophy were both observed. We crossed FS I-I transgenic mice with mdx mice, a model for Duchenne muscular dystrophy. Notably, the skeletal muscles in the mdx/FS I-I mice showed enlargement and reduced cell infiltration. Muscle strength is also recovered in the mdx/FS I-I mice. These results indicate that myostatin blockade by FS I-I has a therapeutic potential for muscular dystrophy.

AB - Myostatin is a potent negative regulator of skeletal muscle growth. Therefore, myostatin inhibition offers a novel therapeutic strategy for muscular dystrophy by restoring skeletal muscle mass and suppressing the progression of muscle degeneration. The known myostatin inhibitors include myostatin propeptide, follistatin, follistatin-related proteins, and myostatin antibodies. Although follistatin shows potent myostatin-inhibiting activities, it also acts as an efficient inhibitor of activins. Because activins are involved in multiple functions in various organs, their blockade by follistatin would affect multiple tissues other than skeletal muscles. In the present study, we report the characterization of a myostatin inhibitor derived from follistatin, which does not affect activin signaling. The dissociation constants (Kd) of follistatin to activin and myostatin are 1.72 nM and 12.3 nM, respectively. By contrast, the dissociation constants (Kd) of a follistatin-derived myostatin inhibitor, designated FS I-I, to activin and myostatin are 64.3 μM and 46.8 nM, respectively. Transgenic mice expressing FS I-I, under the control of a skeletal muscle-specific promoter showed increased skeletal muscle mass and strength. Hyperplasia and hypertrophy were both observed. We crossed FS I-I transgenic mice with mdx mice, a model for Duchenne muscular dystrophy. Notably, the skeletal muscles in the mdx/FS I-I mice showed enlargement and reduced cell infiltration. Muscle strength is also recovered in the mdx/FS I-I mice. These results indicate that myostatin blockade by FS I-I has a therapeutic potential for muscular dystrophy.

UR - http://www.scopus.com/inward/record.url?scp=38949123031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949123031&partnerID=8YFLogxK

U2 - 10.1096/fj.07-8673com

DO - 10.1096/fj.07-8673com

M3 - Article

C2 - 17893249

AN - SCOPUS:38949123031

VL - 22

SP - 477

EP - 487

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 2

ER -